ANDORRA
CERVICAL CANCER PROFILE

Morbidity and Mortality

Crude cervical cancer incidence per 100 000 women (2020): ND
Age-standardized cervical cancer incidence per 100 000 women (2020): ND
Cumulative risk of cervical cancer, ages 0-74 (2020): ND
Cervical cancer deaths (2019): ND
Cervical cancer mortality-to-incidence ratio (2020): ND
Population-based cancer registry exists (2021): No

Primary Prevention

HPV vaccination programme coverage among girls (2020)
Programme coverage:
Coverage by age 15:
0% 20% 40% 60% 80% 100%
0% 20% 40% 60% 80% 100%

HPV vaccination programme (2020):
HPV included in national vaccination programme: Yes
Scale of vaccination programme:
Year of introduction: 2014
Primary target cohort: 12 years

Related risk factors:
Tobacco use prevalence, women aged 15+ years (2020)**: 24%
Condom use at last high-risk sex (-): ND
HIV incidence per 1000, women aged 15+ years (2020): ND

Secondary Prevention

National screening programme for cervical cancer exists (2021): No
Primary screening test used (2021): -
Target age range of programme (2021): -
Programme/guidelines exist to strengthen early detection of first symptoms at primary health care level (2021): No
Clearly defined referral system exists from primary care to secondary and tertiary care (2021): No

Screening for cervical cancer (2019)
Screened in last 5 years
Ever screened:
0% 20% 40% 60% 80% 100%

Treating and Supportive Care

National guidelines on cervical cancer management exist (2021): No

Cancer diagnosis and treatment services generally available (2021):
Cancer centre or cancer department at tertiary level: Yes
Pathology services (laboratories): Yes
Cancer surgery: Yes
Chemotherapy: Yes
Radiotherapy:

Palliative care for patients with NCDs in the public health system generally available (2021):
In primary health care facilities: Yes
In community or home-based care: Yes

WHO Cervical Cancer Elimination Strategy Targets for 2030

90% of girls fully vaccinated with the HPV vaccine by the age of 15
70% of women are screened with a high-performance test by 35 years of age and again by 45 years of age
90% of women identified with cervical disease receive treatment

ND = data not available

* Programme coverage: % of national target population (among 9-14-year-old girls)
† Coverage by age 15: % of population turning 15 that have been vaccinated against HPV at any time between ages 9 to 15

**Data refer to tobacco smoking only, in absence of sufficient data on all tobacco use

World Health Organization - Cervical Cancer Country Profiles, 2021